Background Levamisole has shown clinical benefits in the management of COVID-19 via its immunomodulatory effect. However, the exact role of Levamisole effect in clinical status of COVID-19 patients is unknown. We aimed to evaluate the efficacy of Levamisole on clinical status of patients with COVID-19 during their course of the disease. Methods This prospective, double-blind, randomized controlled clinical trial was performed in adult patients with mild to moderate COVID-19 (room-air oxygen saturation > 94%) from late April 2020 to mid-August 2020. Patients were randomly assigned to receive a 3-day course of Levamisole or placebo in combination with routine standard of care. Results With 25 patients in each arm, 50 patients with COVID-19 were enrolled in the study. Most of the study participants were men (60%). On days 3 and 14, patients in Levamisole group had significantly better cough status distribution when compared to the placebo group (P-value = 0.034 and 0.005, respectively). Moreover, there was significant differences between the two groups in dyspnea at follow-up intervals of 7 (P-value = 0.015) and 14 (P-value = 0.010) days after receiving the interventions. However, no significant difference in fever status was observed on days 1, 3, 7, and 14 in both groups (P-value > 0.05). Conclusion The results of the current study suggest that Levamisole may improve most of clinical status of patients with COVID-19. The patients receiving Levamisole had significantly better chance of clinical status including cough and dyspnea on day 14 when compared to the placebo. However, the effect-size of this finding has uncertain clinical importance. Trial registration The trial was registered as IRCT20190810044500N7 (19/09/2020).
Colchicine has shown clinical benefits in the management of COVID‐19 via its anti‐inflammatory effect. However, the exact role of colchicine in COVID‐19 patients is unknown. The current clinical trial was performed on 202 patients with moderate to severe COVID‐19. Patients were randomly assigned in a 1:1 ratio to receive up to a 3‐day course of 0.5 mg colchicine followed by a 12‐day course of 1 mg colchicine in combination with standard care or a 15‐day course of standard care. Among 202 randomized patients, 153 completed the study and received colchicine/standard care or continued standard care (M age, 54.72 [SD, 15.03] years; 93 [63.1%] men). On day 14, patients in the colchicine/standard care group had significantly higher odds of a better clinical status distribution on chest CT evaluation (p = .048). Based on NYHA classification, the percentage change of dyspnea on day 14 between groups was statistically significant (p = .026), indicating a mean of 31.94% change in the intervention group when compared with 19.95% in the control group. According to this study, colchicine can improve clinical outcomes and reduce pulmonary infiltration in COVID‐19 patients if contraindications and precautions are considered and it is prescribed at the right time and in appropriate cases.
Objectives Basic and clinical studies have shown that magnesium sulphate ameliorates lung injury and controls asthma attacks by anti-inflammatory and bronchodilatory effects. Both intravenous and inhaled magnesium sulphate have a clinical impact on acute severe asthma by inhibition of airway smooth muscle contraction. Besides, magnesium sulphate can dilate constricted pulmonary arteries and reduce pulmonary artery resistance. However, it may affect systemic arteries when administered intravenously. A large number of patients with covid-19 admitted to the hospital suffer from pulmonary involvement. COVID-19 can cause hypoxia due to the involvement of the respiratory airways and parenchyma along with circulatory impairment, which induce ventilation-perfusion mismatch. This condition may result in hypoxemia and low arterial blood oxygen pressure and saturation presented with some degree of dyspnoea and shortness of breath. Inhaled magnesium sulphate as a smooth muscle relaxant (natural calcium antagonist) can cause both bronchodilator and consequently vasodilator effects (via a direct effect on alveolar arterioles in well-ventilated areas) in the respiratory tract. We aim to investigate if inhaled magnesium sulphate as adjuvant therapy to standard treatment can reduce ventilation-perfusion mismatch in the respiratory tract and subsequently improve arterial oxygen saturation in hospitalized patients with COVID-19. Trial design A multi-centre, open-label, randomised controlled trial (RCT) with two parallel arms design (1:1 ratio) Participants Patients aged 18-80 years hospitalized at Masih Daneshvari Hospital and Shahid Dr. Labbafinejad hospital in Tehran and Shahid Sadoughi Hospital in Yazd will be included if they meet the inclusion criteria of the study. Inclusion criteria are defined as 1. Confirmed diagnosis of SARS-CoV-2 infection based on polymerase chain reaction (PCR) of nasopharyngeal secretions or clinical manifestations along with chest computed tomography (chest CT) scan 2. Presenting with moderate or severe COVID-19 lung involvement confirmed with chest CT scan and arterial oxygen saturation below 93% 3. Length of hospital stay ≤48 hours. Patients with underlying cardiovascular diseases including congestive heart failure, bradyarrhythmia, heart block, the myocardial injury will be excluded from the study. Intervention and comparator Participants will be randomly divided into two arms. Patients in the intervention arm will be given both standard treatment for COVID-19 (according to the national guideline) and magnesium sulphate (5 cc of a 20% injectable vial or 2 cc of a 50% injectable vial will be diluted by 50 cc distilled water and nebulized via a mask) every eight hours for five days. Patients in the control (comparator) arm will only receive standard treatment for COVID-19. Main outcomes Improvement of respiratory function and symptoms including arterial blood oxygen saturation, dyspnoea (according to NYHA functional classification), and cough within the first five days of randomization. Randomisation Block randomisation will be used to allocate eligible patients to the study arms (in a 1:1 ratio). Computer software will be applied to randomly select the blocks. Blinding (masking) The study is an open-label RCT without blinding. Numbers to be randomised (sample size) The trial will be performed on 100 patients who will be randomly divided into two arms of control (50) and intervention (50). Trial Status The protocol is Version 5.0, January 05, 2021. Recruitment of the participants started on July 30, 2020, and it is anticipated to be completed by February 28, 2021. Trial registration The trial was registered in the Iranian Registry of Clinical Trials (IRCT) on July 28, 2020. It is available on https://en.irct.ir/trial/49879. The registration number is IRCT20191211045691N1. Full protocol The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting the dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
Antibiotics are a class of drugs that are widely used to eliminate the causes of many infectious diseases around the world. It should be borne in mind that their irrational and irregular administration will increase bacterial resistance and dangerous complications. For this reason, timely diagnosis and usage of antibiotics is one of the tasks of physicians to improve the patient's use of the lowest number of antibiotics. This was a retrospective descriptive cross-sectional study. The samples were selected by non-random sampling from all records of patients admitted to Shahid Sadoughi Hospital of Yazd from HIS hospital system with total number of 82742. The type of hospital admission, the type of prescription, the cause of antibiotic prescription, the cost of antibiotic use was entered into the questionnaire. The most commonly used antibiotics were cefazolin with a frequency of 18.41%, clindamycin with a frequency of 17.49%, ceftriaxone with a frequency of 15.48% and vancomycin with a frequency of 10.18% and metronidazole with a frequency of 7%, respectively. The most costly antibiotics were meropenem (14.28% of costs), vancomycin (13.4%), and amphotericin (10.09%). The pattern of antibiotic use in hospitals should be more carefully considered and given the cost and burden of unnecessary antibiotic use, serious consideration should be given to antibiotic use.
Introduction: Staphylococcus aureus is one of the most important pathogens causing various forms of infection and is a major nosocomial infection agent. In recent years, due to the inappropriate use of antibiotics, drug resistance among microorganisms, including Staphylococcus aureus has increased. This study was conducted to determine the antibiotic resistance pattern of staphylococcus aureus spices isolated from patients referring to Shahid Sadoughi Hospital in Yazd during 2017-2018. Materials and Methods:For this descriptive-analytic study, all positive cultures of Staphylococcus aureus in patients referred to Shahid Sadoughi Hospital in Yazd during 2017-2018 were evaluated. The samples included blood culture, urine culture, wound discharge culture, throat culture, peritoneal culture, pleural culture, synovial culture, CSF culture, bronchial lavage culture. Antibiotic resistance patterns of the samples against 13 different antibiotics were determined by the standard method of Disc Diffusion and data analyzed by SPSS 22 software. Results:The highest antibiotics resistance was seen against Penicillin (92.4%), Tetracycline (52%), Erythromycin (50%), Cefoxitin (40.5%), Doxycycline (36.4%), Ciprofloxacin (34.3%), Clindamycin (33.6%), Cotrimaxazole (25.3%) and the lowest resistance levels were against gentamycin (18.6%). Conclusion:The result of this study similar to the result of other studies shows the high prevalence of drug resistance among Staphylococcus aureus strains that is caused by inappropriate administration of antibiotics. The high sensitivity of Linezolid and Vancomycin shows important role of these antibiotics in treatment of resistance cases.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.